Very different beast from either of those two shares. I like PAR...

Very different beast from either of those two shares. I like PAR but a loose register. And both of them in a crowded space with everyone trying to do cancer.
ILA is a tight register. Top 20 cover 81% of the stock. Running on fumes and a huge unmet need in Dengue.. Dengue is a huge problem and a second dose of dengue is even more dangerous than the first. If they can show a strong result, it will get very interesting. Just annoying they lost 12 months for what I consider a pretty rookie mistake. A strong FDA engagement early could have meant they kicked this study off sometime ago.